Drug Profile
ILV 095
Alternative Names: ILV-095; PF-05212368; PF-5212368; WAY-264095Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antipsoriatics; Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 11 Aug 2011 Discontinued - Phase-I for Psoriasis in Canada (SC)
- 11 Aug 2011 Discontinued - Phase-I for Psoriasis in Japan (SC)
- 11 Aug 2011 Discontinued - Phase-I for Psoriasis in USA (SC)